| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23051 |
| Drug | Fenfluramine |
| Brand | Fintepla® |
| Indication | Fenfluramine (Fintepla®) is indicated for patients (two years of age and older) with Lennox-Gastaut Syndrome as an add-on therapy to other anti-epileptic medicines. |
| Assessment Process | |
| Rapid review commissioned | 09/08/2023 |
| Rapid review completed | 14/09/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/09/2023 |
| Pre-submission consultation with Applicant | 07/11/2023 |
| Full submission received from Applicant | 01/08/2024 |
| Preliminary review sent to Applicant | 07/08/2024 |
| NCPE assessment re-commenced | 02/09/2024 |
| Factual accuracy sent to Applicant | 04/09/2024 |
| NCPE assessment re-commenced | 11/09/2024 |
| NCPE assessment completed | 16/09/2024 |
| NCPE assessment outcome | The NCPE recommends that fenfluramine be considered for reimbursement if cost-effectiveness can be improved.* |
*This recommendation should be considered while also having regards to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
